Tirzepatide Cuts Diabetes Risk By 94% In Prediabetic, Obese Individuals: Trial Results

In those participants who used tirzepatide, there were positive changes in cardiometabolic risk factors such as waist circumference, systolic and diastolic blood pressure, fasting insulin level, and lipid levels. (Credit: Image by Freepik)

Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro and weight loss drug Zepbound, could reduce the risk of developing type 2 diabetes in individuals with prediabetes, overweight, or obesity, according to the trial results.

Eli Lilly tested the safety and efficacy of tirzepatide in long-term weight management and the ability to delay the progression to diabetes in adults with prediabetes, obesity, or overweight in a three-year trial involving 1,032 adults.